Evidence mapPaperPMID 32497744Full record

ReviewDiabetes research and clinical practice2020

Review of methods for detecting glycemic disorders.

Michael Bergman, Muhammad Abdul-Ghani, Ralph A DeFronzo, Melania Manco, Giorgio Sesti, Teresa Vanessa Fiorentino, Antonio Ceriello, Mary Rhee, Lawrence S Phillips, Stephanie Chung and 16 more

Erratum issuedOpen access · greenAbstract readReview
In one paragraph

Review in Diabetes research and clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 98 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 2 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 185 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Marine Oil fromNutrients · 2022
    Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 6 countries.

Michael BergmanNYU School of Medicine, NYU Diabetes Prevention Program, Endocrinology, Diabetes, Metabolism, VA New York Harbor Healthcare System, Manhattan Campus, 423 East 23rd Street, Room 16049C, NY, NY 10010, USA. Electronic address: Michael.Bergman@nyumc.org.
Muhammad Abdul-GhaniDivision of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: abdulghani@uthscsa.edu.
Ralph A DeFronzoDivision of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: defronzo@uthscsa.edu.
Melania MancoResearch Area for Multifactorial Diseases, Bambino Gesù Children Hospital, Rome, Italy. Electronic address: melania.manco@opbg.net.
Giorgio SestiDepartment of Clinical and Molecular Medicine, University of Rome Sapienza, Rome 00161, Italy.
Teresa Vanessa FiorentinoDepartment of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Catanzaro 88100, Italy. Electronic address: vanessa.fiorentino@hotmail.it.
Antonio CerielloDepartment of Cardiovascular and Metabolic Diseases, Istituto Ricerca Cura Carattere Scientifico Multimedica, Sesto, San Giovanni (MI), Italy. Electronic address: antonio.ceriello@hotmail.it.
Mary RheeEmory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA. Electronic address: mrhee@emory.edu.
Lawrence S PhillipsEmory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA. Electronic address: lawrence.phillips@emory.edu.
Stephanie ChungDiabetes Endocrinology and Obesity Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: stephanie.chung@nih.gov.
Celeste CravalhoDiabetes Endocrinology and Obesity Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: celeste.cravalho@nih.gov.
Ram JagannathanEmory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA. Electronic address: ram.jagannathan@emory.edu.
Louis MonnierInstitute of Clinical Research, University of Montpellier, Montpellier, France. Electronic address: louis.monnier@inserm.fr.
Claude ColetteInstitute of Clinical Research, University of Montpellier, Montpellier, France. Electronic address: dr.claudecolette@gmail.com.
David OwensDiabetes Research Group, Institute of Life Science, Swansea University, Wales, UK. Electronic address: owensdr@cardiff.ac.uk.
Cristina BianchiUniversity Hospital of Pisa, Section of Metabolic Diseases and Diabetes, University Hospital, University of Pisa, Pisa, Italy. Electronic address: cribianchi@hotmail.com.
Stefano Del PratoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: stefano.delprato@med.unipi.it.
Mariana P MonteiroEndocrine, Cardiovascular & Metabolic Research, Unit for Multidisciplinary Research in Biomedicine (UMIB), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal. Electronic address: mpmonteiro@icbas.up.pt.
João Sérgio NevesDepartment of Surgery and Physiology, Cardiovascular Research and Development Center, Faculty of Medicine, University of Porto, Porto, Portugal; Department of Endocrinology, Diabetes and Metabolism, São João University Hospital Center, Porto, Portugal. Electronic address: jsneves@med.up.pt.
Jose Luiz MedinaPorto University, Porto Medical School, Porto, Portugal.
Maria Paula MacedoCEDOC-Centro de Estudos de Doenças Crónicas, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal; APDP-Diabetes Portugal, Education and Research Center (APDP-ERC), Lisboa, Portugal. Electronic address: paula.macedo@nms.unl.pt.
Rogério Tavares RibeiroInstitute for Biomedicine, Department of Medical Sciences, University of Aveiro, APDP Diabetes Portugal, Education and Research Center (APDP-ERC), Aveiro, Portugal. Electronic address: rogerio.ribeiro@apdp.pt.
João Filipe RaposoCEDOC-Centro de Estudos de Doenças Crónicas, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal; APDP-Diabetes Portugal, Education and Research Center (APDP-ERC), Lisboa, Portugal. Electronic address: filipe.raposo@sapo.pt.
Brenda DorcelyNYU School of Medicine, Division of Endocrinology, Diabetes, Metabolism, NY, NY 10016, USA. Electronic address: brenda.dorcely@nyulangone.org.
Nouran IbrahimNYU School of Medicine, Division of Endocrinology, Diabetes, Metabolism, NY, NY 10016, USA. Electronic address: nouran.ibrahim@nyulangone.org.
Martin BuysschaertDepartment of Endocrinology and Diabetology, Université Catholique de Louvain, University Clinic Saint-Luc, Brussels, Belgium. Electronic address: martin.buysschaert@uclouvain.be.
Emory University · USNational Institutes of Health · USNew York University · USThe University of Texas Health Science Center at San Antonio · USUniversité de Montpellier · FRUniversity of Pisa · ITAssociacao Protectora dos Diabeticos de Portugal · PTAtlanta VA Health Care System · USBambino Gesù Children's Hospital · ITHospital de São João · PTMagna Graecia University · ITMultiMedica · ITSapienza University of Rome · ITSwansea University · GBUCLouvain · BEUniversidade do Porto · PTUniversidade Lusófona do Porto · PTUniversidade Nova de Lisboa · PTUniversity of Aveiro · PTVA NY Harbor Healthcare System · US

Funding

Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) StudyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Heidi Krause-Steinrauf, JOHN M LACHIN · 2021 to 2022
$21.0M
SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · YALE UNIVERSITY · 1986 to 2025
$3.6M
Technologies Advancing Translation - Regional CoreP30DK111024 · EMORY UNIVERSITY · 2025 to 2025
$775k
Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset DiabetesR01DK097554 · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2025 to 2025
$685k
Training Program in Cardiometabolic DiseasesT32HL098129 · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2025 to 2025
$606k
Ketones, Muscle Metabolism, and SGLT2 InhibitorsR01DK107680 · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2025 to 2025
$583k
Investigation of Heart and Vascular Outcomes in Older VeteransI01CX001025 · VETERANS HEALTH ADMINISTRATION · 2025 to 2025
CSRD VA I01 CX001025CSRD VA I01 CX001737NHLBI NIH HHS T32 HL098129NIAID NIH HHS R03 AI133172NIDDK NIH HHS P30 DK111024NIDDK NIH HHS R01 DK024092NIDDK NIH HHS R01 DK097554NIDDK NIH HHS R01 DK107680NIDDK NIH HHS R21 DK099716NIDDK NIH HHS U01 DK098246NIDDK NIH HHS U34 DK091958RRD VA IK2 RX002928
6 · The paper itself

Abstract

Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkersBlood GlucoseBlood Glucose Self-MonitoringCardiovascular DiseasesChildDiabetes Mellitus, Type 2FemaleFructosamineGlucose IntoleranceGlucose Metabolism DisordersGlucose Tolerance TestGlycated HemoglobinBiomarkersBlood GlucoseFructosamineGlycated HemoglobinGlycated Serum AlbuminGlycation End Products, AdvancedSerum AlbuminBiomarkersCardiovascular diseaseContinuous glucose monitoringGlycemic variabilityHbA1cMetabolomicsOral glucose tolerance testPrediabetesType 2 diabetes

Identifiers

PMID32497744
PMCPMC7977482
OpenAlexW3032874471

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.